87 related articles for article (PubMed ID: 28888341)
1. HLA based selection of epitopes offers a potential window of opportunity for vaccine design against HIV.
Sundaramurthi JC; Ashokkumar M; Swaminathan S; Hanna LE
Vaccine; 2017 Oct; 35(42):5568-5575. PubMed ID: 28888341
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Vaccine Against HIV, Viral Variability, Cytotoxic T Lymphocyte Epitopes, and Genetics of Patients.
Fleury H; Tumiotto C; Bellecave P; Recordon-Pinson P
AIDS Res Hum Retroviruses; 2018 Jan; 34(1):27-30. PubMed ID: 28899104
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of sequences around HIV-1 protease cleavage sites: potential targets and population coverage analysis for a HIV vaccine targeting protease cleavage sites.
Luo M; Capina R; Daniuk C; Tuff J; Peters H; Kimani M; Wachihi C; Kimani J; Ball TB; Plummer FA
Vaccine; 2013 Jun; 31(29):3000-8. PubMed ID: 23664989
[TBL] [Abstract][Full Text] [Related]
4. Resistance-associated epitopes of HIV-1C-highly probable candidates for a multi-epitope vaccine.
Sundaramurthi JC; Swaminathan S; Hanna LE
Immunogenetics; 2012 Oct; 64(10):767-72. PubMed ID: 22810271
[TBL] [Abstract][Full Text] [Related]
5. HIV/AIDS. HLA leaves its footprints on HIV.
McMichael A; Klenerman P
Science; 2002 May; 296(5572):1410-1. PubMed ID: 12029119
[No Abstract] [Full Text] [Related]
6. Short communication: HIV-1 Nef protein carries multiple epitopes suitable for induction of cellular immunity for an HIV vaccine in Africa.
Kilpeläinen A; Axelsson Robertson R; Leitner T; Sandström E; Maeurer M; Wahren B
AIDS Res Hum Retroviruses; 2014 Nov; 30(11):1065-71. PubMed ID: 24866397
[TBL] [Abstract][Full Text] [Related]
7. HLA class I associations with rates of HIV-1 seroconversion and disease progression in the Pumwani Sex Worker Cohort.
Peterson TA; Kimani J; Wachihi C; Bielawny T; Mendoza L; Thavaneswaran S; Narayansingh MJ; Kariri T; Liang B; Ball TB; Ngugi EN; Plummer FA; Luo M
Tissue Antigens; 2013 Feb; 81(2):93-107. PubMed ID: 23330720
[TBL] [Abstract][Full Text] [Related]
8. Human leucocyte antigen supertypes and immune susceptibility to HIV-1, implications for vaccine design.
MacDonald KS; Matukas L; Embree JE; Fowke K; Kimani J; Nagelkerke NJ; Oyugi J; Kiama P; Kaul R; Luscher MA; Rowland-Jones S; Ndinya-Achola J; Ngugi E; Bwayo JJ; Plummer FA
Immunol Lett; 2001 Nov; 79(1-2):151-7. PubMed ID: 11595302
[TBL] [Abstract][Full Text] [Related]
9. HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8(+) T Cell Response against HIV-1.
Altfeld M; Kalife ET; Qi Y; Streeck H; Lichterfeld M; Johnston MN; Burgett N; Swartz ME; Yang A; Alter G; Yu XG; Meier A; Rockstroh JK; Allen TM; Jessen H; Rosenberg ES; Carrington M; Walker BD
PLoS Med; 2006 Oct; 3(10):e403. PubMed ID: 17076553
[TBL] [Abstract][Full Text] [Related]
10. Relative dominance of epitope-specific cytotoxic T-lymphocyte responses in human immunodeficiency virus type 1-infected persons with shared HLA alleles.
Day CL; Shea AK; Altfeld MA; Olson DP; Buchbinder SP; Hecht FM; Rosenberg ES; Walker BD; Kalams SA
J Virol; 2001 Jul; 75(14):6279-91. PubMed ID: 11413294
[TBL] [Abstract][Full Text] [Related]
11. Comparison of HIV-1 nef and gag Variations and Host HLA Characteristics as Determinants of Disease Progression among HIV-1 Vertically Infected Kenyan Children.
Saina MC; Bi X; Lihana R; Lwembe R; Ishizaki A; Panikulam A; Palakudy T; Musoke R; Owens M; Songok EM; Ichimura H
PLoS One; 2015; 10(8):e0137140. PubMed ID: 26317223
[TBL] [Abstract][Full Text] [Related]
12. Multiple Approaches for Increasing the Immunogenicity of an Epitope-Based Anti-HIV Vaccine.
Rosa DS; Ribeiro SP; Fonseca SG; Almeida RR; Santana VC; Apostólico Jde S; Kalil J; Cunha-Neto E
AIDS Res Hum Retroviruses; 2015 Nov; 31(11):1077-88. PubMed ID: 26149745
[TBL] [Abstract][Full Text] [Related]
13. Breadth of HIV-1 Env-specific antibody-dependent cellular cytotoxicity: relevance to global HIV vaccine design.
Madhavi V; Wren LH; Center RJ; Gonelli C; Winnall WR; Parsons MS; Kramski M; Kent SJ; Stratov I
AIDS; 2014 Aug; 28(13):1859-70. PubMed ID: 24937308
[TBL] [Abstract][Full Text] [Related]
14. Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines.
Ferrari G; Kostyu DD; Cox J; Dawson DV; Flores J; Weinhold KJ; Osmanov S
AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1433-43. PubMed ID: 11018863
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 adaptation to HLA: a window into virus-host immune interactions.
Carlson JM; Le AQ; Shahid A; Brumme ZL
Trends Microbiol; 2015 Apr; 23(4):212-24. PubMed ID: 25613992
[TBL] [Abstract][Full Text] [Related]
16. HIV and HLA class I: an evolving relationship.
Goulder PJ; Walker BD
Immunity; 2012 Sep; 37(3):426-40. PubMed ID: 22999948
[TBL] [Abstract][Full Text] [Related]
17. Progression of HIV to AIDS: a protective role for HLA-B27?
den Uyl D; van der Horst-Bruinsma IE; van Agtmael M
AIDS Rev; 2004; 6(2):89-96. PubMed ID: 15332431
[TBL] [Abstract][Full Text] [Related]
18. Sequence analysis of HIV-1 isolates from Guinea-Bissau: selection of vaccine epitopes relevant in both West African and European countries.
Vinner L; Holmgren B; Jensen KJ; Esbjornsson J; Borggren M; Hentze JL; Karlsson I; Andresen BS; Gram GJ; Kloverpris H; Aaby P; Da Silva ZJ; Fenyö EM; Fomsgaard A
APMIS; 2011 Aug; 119(8):487-97. PubMed ID: 21749448
[TBL] [Abstract][Full Text] [Related]
19. The majority of currently circulating human immunodeficiency virus type 1 clade B viruses fail to prime cytotoxic T-lymphocyte responses against an otherwise immunodominant HLA-A2-restricted epitope: implications for vaccine design.
Altfeld M; Allen TM; Kalife ET; Frahm N; Addo MM; Mothe BR; Rathod A; Reyor LL; Harlow J; Yu XG; Perkins B; Robinson LK; Sidney J; Alter G; Lichterfeld M; Sette A; Rosenberg ES; Goulder PJ; Brander C; Walker BD
J Virol; 2005 Apr; 79(8):5000-5. PubMed ID: 15795285
[TBL] [Abstract][Full Text] [Related]
20. Loss of HIV-1-derived cytotoxic T lymphocyte epitopes restricted by protective HLA-B alleles during the HIV-1 epidemic.
Schellens IM; Navis M; van Deutekom HW; Boeser-Nunnink B; Berkhout B; Kootstra N; Miedema F; Keşmir C; Schuitemaker H; van Baarle D; Borghans JA
AIDS; 2011 Sep; 25(14):1691-700. PubMed ID: 21681058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
